Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 180 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

 		Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis Phase2

Home Reported Outcomes in PNH

 		Paroxysmal Nocturnal Hemoglobinuria

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

 		Breast Cancer Phase1, Phase2

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

 		Steroid-refractory Acute Graft Versus Host Disease Phase4

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

 		Hypercholesterolemia Phase4

Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

 		Hidradenitis Suppurativa

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

 		Lupus Nephritis

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

 		Atypical Hemolytic Uremic Syndrome Phase3

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

 		Atypical Hemolytic Uremic Syndrome Phase3

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

 		Giant Cell Arteritis, Polymyalgia Rheumatica Phase1